Related Experiment Video
Updated: Nov 16, 2025
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia
1Medical Biochemistry Department, Medical Research Division, National Research Centre, 33 El Bohouth St. (Former El Tahrir St.), Dokki, P.O. 12622, Giza, Egypt.
Insights
Intravenous immunoglobulin (IVIg) offers a safe treatment option for COVID-19 patients, potentially improving survival rates. Passive immunization with IVIg may enhance the immune response against the virus.
Area of Science:
- Immunology
- Virology
- Infectious Diseases
Background:
- The COVID-19 pandemic necessitates rapid therapeutic interventions.
- Lymphocytopenia is a common complication in COVID-19 patients.
- Vaccine and antiviral development timelines are lengthy.
Purpose of the Study:
- To explore the potential of intravenous immunoglobulin (IVIg) as a safe treatment for COVID-19.
- To assess IVIg's role in managing immunodeficiency and lymphocytopenia associated with COVID-19.
Main Methods:
- Review of existing clinical data and research on IVIg efficacy.
- Analysis of passive immunization strategies in viral infections.
Main Results:
- IVIg may serve as a safe clinical treatment for COVID-19 patients.
- IVIg can potentially improve the quality of life for patients with COVID-19 related immunodeficiency.
Conclusions:
- Passive immunization with IVIg can bolster the immune system to combat the virus.
- Enhanced efficacy of IVIg immunotherapy is possible through convalescent plasma-derived antibodies.
Background:
The global coronavirus disease 2019 (COVID-19) was announced as pandemic by the World Health Organization (WHO). With the increased number of infected and dead victims daily all over the world, it becomes necessary to stop or overcome its rapid spread.Main bodyAlthough the production of vaccine or even specified effective anti-virus may take about six months to a year, intravenous immunoglobulin (IVIg) may be clinically used as a safe treatment to save and improve the quality of life of patients with a variety of immunodeficiency diseases such as lymphocytopenia, which is a common clinical feature in COVID-19.
Conclusion:
Through the current review, it was concluded that this passive immunization may promote the immunity to better fight against the virus, so the survival of the patients could be kept longer. The efficacy of immunotherapy with IVIg would be greater if the immune IgG antibodies were collected from convalescent plasma therapy.
Related Concept Videos
01:27Tumor Immunotherapy
01:25Immunodeficiency Diseases
There are three main causes of immunodeficiency...
01:36Humoral Immune Responses
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...